Leading Companies Fueling Innovation and Growth in the Hereditary Angioedema Market

The hereditary angioedema market is on track for significant expansion in the coming years, driven by advances in treatment options and growing awareness of this rare condition. Innovations in therapy and diagnostics are transforming patient care, creating promising prospects for market players and patients alike. Here is a detailed overview of the market size, key players, emerging trends, and segmentation.

Projected Market Growth and Size of the Hereditary Angioedema Market
The hereditary angioedema market is expected to reach a valuation of $4.15 billion by 2030, growing at a compound annual growth rate (CAGR) of 8.0%. This expansion is fueled by the introduction of new oral and subcutaneous therapies, increased investment in the development of rare disease drugs, and a surge in personalized medicine approaches. Additionally, the market benefits from advancements in genetic screening programs and improved strategies for long-term disease management. Noteworthy trends shaping the market include greater use of targeted bradykinin therapies, a rise in prophylactic treatment regimens, an emphasis on early genetic diagnosis, growth in home-based self-administration therapies, and more patient-centric treatment models.

Download a free report of the hereditary angioedema market report:
https://www.thebusinessresearchcompany.com/report/hereditary-angioedema-global-market-report?utm_source=OpenPR&utm_medium=Paid&utm_campaign=Apr_PR

Factors Positively Impacting the Hereditary Angioedema Market
The growth of novel treatments, especially oral and subcutaneous options, is revolutionizing disease management and enhancing patient convenience. These new therapies are encouraging wider adoption among healthcare providers and patients.
In parallel, the expansion of genetic screening programs allows for earlier and more accurate diagnosis, which is critical for timely intervention. This, combined with increased focus on personalized medicine, enables tailored treatment plans that improve patient outcomes and drive market demand.

Key Players Steering the Hereditary Angioedema Industry
The hereditary angioedema market is shaped by several leading pharmaceutical and biotech companies, including:
Takeda Pharmaceutical Company Limited, CSL Limited, Sanofi S.A., Pharming Group N.V., BioCryst Pharmaceuticals Inc., KalVista Pharmaceuticals Inc., Ionis Pharmaceuticals Inc., Intellia Therapeutics Inc., Arrowhead Pharmaceuticals Inc., Astria Therapeutics Inc., Pharvaris N.V., Adverum Biotechnologies Inc., ADARx Pharmaceuticals Inc., Attune Pharmaceuticals Inc., Lev Pharmaceuticals Inc., BioMarin Pharmaceutical Inc., Spark Therapeutics Inc., Otsuka Pharmaceutical Co. Ltd., Pfizer Inc., Regeneron Pharmaceuticals Inc., Vertex Pharmaceuticals Incorporated, and Alnylam Pharmaceuticals Inc.

View the full hereditary angioedema market report:
https://www.thebusinessresearchcompany.com/report/hereditary-angioedema-global-market-report?utm_source=OpenPR&utm_medium=Paid&utm_campaign=Apr_PR

Strategic Alliances Enhance Market Presence and Accessibility
In July 2023, US-based BioCryst Pharmaceuticals entered into a partnership with Turkey's Er-Kim Pharmaceuticals to commercialize ORLADEYO (berotralstat) in the Turkish market. This collaboration aims to improve access to this hereditary angioedema treatment for patients in Turkey while bolstering BioCryst's footprint in the global rare disease arena. Er-Kim Pharmaceuticals specializes in producing and marketing high-quality medicines across multiple therapeutic categories.

Future Trends in the Hereditary Angioedema Market
Companies in this sector are increasingly focused on forming strategic partnerships that enable them to enter new markets and expand their customer base more effectively. Such alliances allow firms to pool resources and expertise to reach common goals swiftly.
For example, in January 2025, Dutch company QIAGEN partnered with UK-based Genomics England to launch the Generation Study. This initiative aims to sequence the genomes of 100,000 newborns in England to screen for over 200 actionable genetic diseases. QIAGEN is providing clinically relevant variant data for genes included in the point-of-care sequencing test, helping speed up diagnosis and treatment. The study, officially starting in October 2024, targets rare conditions potentially affecting about 3,000 newborns annually in the UK.

Detailed Breakdown of Hereditary Angioedema Market Segments
This report analyzes the hereditary angioedema market across several key segments:
1) By Type:
- Hereditary Angioedema Type I
- Hereditary Angioedema Type II
2) By Treatment Type:
- Prophylaxis
- On-demand
3) By Drug Class:
- C-1 Esterase Inhibitors
- Bradykinin Receptor Antagonist
- Kallikrein Inhibitors
- Other Drug Classes
4) By Route of Administration:
- Subcutaneous
- Intravenous
- Oral
5) By Distribution Channel:
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies

Further subcategories include:
- For Hereditary Angioedema Type I: C1-Inhibitor Deficiency and Low C1-Inhibitor Levels
- For Hereditary Angioedema Type II: Normal C1-Inhibitor Levels, Dysfunctional C1-Inhibitor, and Genetic Mutations in the SERPING1 Gene

This comprehensive segmentation delivers a detailed understanding of the market landscape and the specific areas driving growth and innovation.

Reach out to us:
The Business Research Company: https://www.thebusinessresearchcompany.com/,
Americas +1 310-496-7795,
Europe +44 7882 955267,
Asia & Others +44 7882 955267 & +91 8897263534,
Email us at info@tbrc.info.

Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company,
Twitter: https://twitter.com/tbrc_info,
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Learn More About The Business Research Company
With over 17500+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead.Our flagship product, the Global Market Model (GMM), is a premier market intelligence platform delivering comprehensive and updated forecasts to support informed decision-making.

This release was published on openPR.